Related Experiment Video
Updated: Jun 13, 2026
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Central nervous system multiple myeloma: An update for 2026.
Boyu Wang1, Wenjing Li2, Menghan Liu2
1Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Annals of Hematology
|June 11, 2026
Summary
Central nervous system multiple myeloma (CNS-MM) is a rare, aggressive cancer. Modern treatments like immunotherapy show promise, but more research is needed for better outcomes.
Area of Science:
- Hematology
- Neurology
- Oncology
Background:
- Central nervous system multiple myeloma (CNS-MM) is a rare, aggressive plasma cell disorder.
- It presents unique diagnostic challenges and resistance to conventional therapies, leading to poor prognoses.
Purpose of the Study:
- To review current evidence on CNS-MM epidemiology, risk factors, diagnostics, and therapeutics.
- To highlight emerging immunotherapeutic approaches and identify knowledge gaps.
Main Methods:
- Literature review synthesizing current evidence on CNS-MM.
- Analysis of diagnostic modalities including neurological symptoms, CSF flow cytometry, and advanced imaging.
- Evaluation of therapeutic strategies, including conventional therapies, radiotherapy, BBB-penetrating agents, and novel immunotherapies.
Main Results:
- Conventional therapies offer dismal outcomes for CNS-MM, with median survival in months.
- Modern diagnosis integrates clinical, cytological, and imaging data, though unified criteria are absent.
- Emerging immunotherapies, including bispecific antibodies and CAR-T therapy, show high CNS-specific response rates in limited data.
Conclusions:
- CNS-MM requires multimodal treatment strategies incorporating novel approaches.
- Immunotherapy, particularly bispecific antibodies and CAR-T, offers unprecedented efficacy but requires further investigation.
- Addressing knowledge gaps in epidemiology, diagnostics, and therapeutics is crucial for improving CNS-MM patient outcomes.
